On Tuesday, KBR, Inc. (NYSE:KBR)’s shares inclined 0.70% to $20.17.
KBR, Inc. (KBR) in a joint venture with Kvaerner has signed a contract with Statoil for the complete delivery of platform topsides to the Johan Sverdrup field development. The agreement to deliver the deck for the utility and living quarter (ULQ) platform comes after a tough international competition, where Kvaerner-KBR presented the best overall bid. The agreement has an estimated total value for the Kvaerner-KBR partnership of about NOK 6.7 billion.
The ULQ-platform is one of four platforms to the Phase One development of the Johan Sverdrup oil and gas field on the Norwegian continental shelf. Kvaerner-KBR joint venture will execute the engineering, procurement and construction (EPC) for the ULQ topside as one complete delivery. The agreement also comprises an option for commissioning assistance and offshore hook-up for the platform.
KBR, Inc. operates as an engineering, construction, and services company worldwide. The company operates through three segments: Technology & Consulting, Engineering & Construction, and Government Services. The Technology & Consulting segment offers various services and solutions, counting licensing, engineering and design, proprietary equipment, plant automation, catalysts, and related consulting services to hydrocarbons, chemicals, and fertilizer markets.
Carnival Corp (NYSE:CCL)’s shares gained 0.38% to $47.20.
Carnival Corp (CCL) named Tara Russell president of fathom and Global Impact Lead of Carnival Corporation & plc. In this newly created role, Russell will oversee all aspects of fathom, a new brand from Carnival Corporation whose unique business model for sustained impact and lasting development creates a brand with size, scale and global vision that reaches beyond what the world has ever seen.
Under Russell’s direction, fathom will offer travelers unique opportunities to become immersed in another culture, work alongside its people to create enduring, life-changing impact, and build community with like-minded travelers – all on a scale never before seen. As the corporation’s Global Impact Lead, she will work with Carnival Corporation’s 10 brands on social impact strategies and opportunities. Russell generated the idea and vision for fathom in 2013 and has been working since January 2014 to research, design and develop the brand’s business model.
Carnival Corporation operates as a cruise company worldwide. It provides vacations to various cruise destinations. The company offers cruise services under the Carnival Cruise Lines, Holland America Line, Princess Cruises, and Seabourn brand names in North America; and AIDA Cruises, Costa Cruises, Cunard, and P&O Cruises names in Europe, Australia, and Asia. It operates 100 cruise ships.
At the end of Tuesday’s trade, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘s shares dipped -2.86% to $2.21.
AVEO Pharmaceuticals, Inc. (AVEO) declared that it has “written confirmation” from European regulators in support of a submission of its drug, tivozanib, for approval to treat kidney cancer. That drug underwent a late stage trial in 314 patients who had already tried other drugs.
The results of that trial, which ended in 2012, showed that while the drug appeared to stop the progression of the cancer for a few months, it did not extend overall survival of patients. The company has argued that that lack of overall survival benefit was because it allowed patients in the control arm of the trial whose cancer had progressed to take tivozanib, essentially treating them with two drugs and prolonging their lives contrast to those who had taken tivozanib since the start of the trial.
Despite that argument, the U.S. Food and Drug Administration rejected an application for approval of the drug in 2013. But news seems to indicate that European regulators are buying it, and importantly, the company says they are not asking for another trial of the drug.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development comprise Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has accomplished Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has accomplished a Phase I dose escalation study.
Humana Inc (NYSE:HUM), ended its Tuesday’s trading session with 0.07% gain, and closed at $212.47.
Humana Inc (HUM) declared that they have partnered on a new Accountable Care arrangement designed to improve the wellness and care experience for a growing population of more than 3,000 Medicare Advantage members in Lancaster County.
The agreement became effective April 1 and reflects a shift in the health care system away from the current episodic model to place greater emphasis on health outcomes, preventive care and patient care experiences. Accountable care arrangements with rewards for quality and efficiency are emerging as payment innovation efforts and are being deployed across Pennsylvania and the United States. The LG Health/Humana partnership has established focused quality and cost aims that, if attained, will generate savings for individuals and employers.
The accountable care arrangement with Humana is being undertaken specifically by LG Health’s accountable care organization, the LG Health Community Care Collaborative, which launched in 2014.
Humana Inc., together with its auxiliaries, operates as a health and well-being company. The company operates through three segments: Retail, Employer Group, and Healthcare Services. The Retail segment provides Medicare and commercial fully-insured medical and specialty health insurance benefits, counting dental, vision, and other supplemental health and financial protection products directly to individuals.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
